CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Olema Pharmaceuticals, Inc. - OLMA CFD

12.85
15.4%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026346 %
Charges from full value of position ($-5.01)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026346%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004124 %
Charges from full value of position ($0.78)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 15.19
Open* 14.77
1-Year Change* 453.18%
Day's Range* 12.85 - 15.22
52 wk Range 2.19-17.79
Average Volume (10 days) 616.10K
Average Volume (3 months) 8.57M
Market Cap 777.73M
P/E Ratio -100.00K
Shares Outstanding 54.77M
Revenue N/A
EPS -2.32
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 4, 2023 15.19 0.61 4.18% 14.58 15.44 14.42
Dec 1, 2023 14.55 0.88 6.44% 13.67 14.57 13.50
Nov 30, 2023 13.93 0.91 6.99% 13.02 14.60 12.24
Nov 29, 2023 13.12 -0.50 -3.67% 13.62 13.76 12.87
Nov 28, 2023 13.51 0.35 2.66% 13.16 13.51 12.11
Nov 27, 2023 13.16 -1.11 -7.78% 14.27 14.37 13.07
Nov 24, 2023 13.84 0.24 1.76% 13.60 14.06 13.60
Nov 22, 2023 13.71 -0.46 -3.25% 14.17 14.40 13.59
Nov 21, 2023 14.16 -1.66 -10.49% 15.82 15.82 14.14
Nov 20, 2023 15.90 -0.01 -0.06% 15.91 16.06 15.48
Nov 17, 2023 15.87 -0.88 -5.25% 16.75 16.91 15.70
Nov 16, 2023 16.77 -0.10 -0.59% 16.87 16.87 15.93
Nov 15, 2023 16.77 0.80 5.01% 15.97 17.11 15.97
Nov 14, 2023 15.83 0.70 4.63% 15.13 16.12 14.98
Nov 13, 2023 14.70 -0.77 -4.98% 15.47 15.49 14.57
Nov 10, 2023 15.79 -0.38 -2.35% 16.17 16.57 15.27
Nov 9, 2023 16.09 -0.78 -4.62% 16.87 17.24 15.89
Nov 8, 2023 17.07 0.45 2.71% 16.62 17.62 15.47
Nov 7, 2023 16.57 1.52 10.10% 15.05 16.71 15.05
Nov 6, 2023 15.00 -1.62 -9.75% 16.62 16.72 13.53

Olema Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Friday, December 8, 2023

Time (UTC)

13:00

Country

US

Event

Olema Pharmaceuticals Inc to Host Call for Analysts and Investors
Olema Pharmaceuticals Inc to Host Call for Analysts and Investors

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Olema Pharmaceuticals Inc Earnings Release
Q4 2023 Olema Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 106.988 71.491 21.528 4.323 2.173
Selling/General/Admin. Expenses, Total 24.714 20.391 7.824 0.403 0.386
Research & Development 82.274 51.1 13.704 3.92 1.693
Unusual Expense (Income) 0 0.094
Operating Income -106.988 -71.491 -21.528 -4.323 -2.173
Interest Income (Expense), Net Non-Operating 2.228 0.442 -0.593 0.007 -0.024
Other, Net -0.027 -0.047 0 0
Net Income Before Taxes -104.787 -71.096 -22.121 -4.316 -2.197
Net Income After Taxes -104.787 -71.096 -22.121 -4.316 -2.197
Net Income Before Extra. Items -104.787 -71.096 -22.121 -4.316 -2.197
Net Income -104.787 -71.096 -22.121 -4.316 -2.197
Total Adjustments to Net Income 0 -1.869 0 0
Income Available to Common Excl. Extra. Items -104.787 -71.096 -23.99 -4.316 -2.197
Income Available to Common Incl. Extra. Items -104.787 -71.096 -23.99 -4.316 -2.197
Diluted Net Income -104.787 -71.096 -23.99 -4.316 -2.197
Diluted Weighted Average Shares 39.9955 39.5243 38.5197 38.5197 38.5197
Diluted EPS Excluding Extraordinary Items -2.61997 -1.79879 -0.6228 -0.11205 -0.05704
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.61997 -1.79879 -0.6228 -0.11205 -0.0546
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 21.601 29.602 27.219 23.222 33.293
Selling/General/Admin. Expenses, Total 3.612 6.776 5.635 5.595 6.239
Research & Development 17.989 22.826 21.584 17.627 27.054
Operating Income -21.601 -29.602 -27.219 -23.222 -33.293
Interest Income (Expense), Net Non-Operating 1.55 1.305 0.973 0.622 0.415
Net Income Before Taxes -20.095 -28.286 -26.179 -22.72 -32.858
Net Income After Taxes -20.095 -28.286 -26.179 -22.72 -32.858
Net Income Before Extra. Items -20.095 -28.286 -26.179 -22.72 -32.858
Net Income -20.095 -28.286 -26.179 -22.72 -32.858
Income Available to Common Excl. Extra. Items -20.095 -28.286 -26.179 -22.72 -32.858
Income Available to Common Incl. Extra. Items -20.095 -28.286 -26.179 -22.72 -32.858
Diluted Net Income -20.095 -28.286 -26.179 -22.72 -32.858
Diluted Weighted Average Shares 40.7203 40.3545 40.1906 40.0362 39.9182
Diluted EPS Excluding Extraordinary Items -0.49349 -0.70094 -0.65137 -0.56749 -0.82313
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.49349 -0.70094 -0.65137 -0.56749 -0.82313
Other, Net -0.044 0.011 0.067 -0.12 0.02
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 208.899 290.685 342.137 0.103 3.242
Cash and Short Term Investments 204.421 287.25 338.549 0.068 3.149
Cash & Equivalents 23.702 13.812 338.549 0.068 3.149
Prepaid Expenses 2.655 3.212 3.439 0 0
Other Current Assets, Total 1.504 0.223 0.149 0.035 0.093
Total Assets 215.645 295.945 342.722 0.132 3.271
Property/Plant/Equipment, Total - Net 3.975 4.72 0.075 0.026 0.026
Property/Plant/Equipment, Total - Gross 4.556 4.944 0.106 0.097
Accumulated Depreciation, Total -0.581 -0.224 -0.08 -0.071
Other Long Term Assets, Total 2.771 0.54 0.51 0.003 0.003
Total Current Liabilities 16.549 9.019 4.585 1.378 0.201
Accounts Payable 0.374 0.023 0.719 0.935 0.116
Accrued Expenses 16.025 8.53 3.494 0 0
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.15 0.466 0.372 0.443 0.085
Total Liabilities 18.099 11.377 4.585 1.378 0.201
Total Long Term Debt 0 0 0 0 0
Total Equity 197.546 284.568 338.137 -1.246 3.07
Redeemable Preferred Stock 0 0 0 9.348 9.348
Common Stock 0.003 0.003 0.003 0 0
Additional Paid-In Capital 408.333 388.904 371.228 0.168 0.168
Retained Earnings (Accumulated Deficit) -208.977 -104.19 -33.094 -10.762 -6.446
Total Liabilities & Shareholders’ Equity 215.645 295.945 342.722 0.132 3.271
Total Common Shares Outstanding 40.2871 39.7973 39.3082 38.5197 38.5197
Short Term Investments 180.719 273.438
Other Liabilities, Total 1.55 2.358
Other Equity, Total -1.813 -0.149
Total Receivables, Net 0.319
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 282.008 171.509 189.397 208.899 225.058
Cash and Short Term Investments 276.901 167.444 185.954 204.421 222.6
Cash & Equivalents 117.407 34.958 40.918 23.702 26.804
Short Term Investments 159.494 132.486 145.036 180.719 195.796
Prepaid Expenses 4.414 3.607 3.069 2.655 1.298
Other Current Assets, Total 0.274 0.237 0.072 1.504 1.16
Total Assets 292.799 177.624 195.768 215.645 231.997
Property/Plant/Equipment, Total - Net 3.614 3.211 3.6 3.975 4.168
Property/Plant/Equipment, Total - Gross 4.312 3.955 4.281 4.556 4.652
Accumulated Depreciation, Total -0.698 -0.744 -0.681 -0.581 -0.484
Other Long Term Assets, Total 7.177 2.904 2.771 2.771 2.771
Total Current Liabilities 15.966 14.831 19.41 16.549 12.552
Accounts Payable 2.207 1.625 0.681 0.374 0.014
Accrued Expenses 13.702 13.094 18.569 16.025 12.278
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.057 0.112 0.16 0.15 0.26
Total Liabilities 17.665 16.041 20.793 18.099 14.298
Total Long Term Debt 0 0 0 0 0
Total Equity 275.134 161.583 174.975 197.546 217.699
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.004 0.003 0.003 0.003 0.003
Additional Paid-In Capital 554.231 419.456 413.213 408.333 403.168
Retained Earnings (Accumulated Deficit) -278.86 -257.358 -237.263 -208.977 -182.798
Other Equity, Total -0.241 -0.518 -0.978 -1.813 -2.674
Total Liabilities & Shareholders’ Equity 292.799 177.624 195.768 215.645 231.997
Total Common Shares Outstanding 54.6015 41.3244 40.4383 40.2871 40.0846
Other Liabilities, Total 1.699 1.21 1.383 1.55 1.746
Total Receivables, Net 0.419 0.221 0.302 0.319
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -104.787 -71.096 -22.121 -4.316 -2.197
Cash From Operating Activities -82.065 -50.69 -19.866 -3.081 -2.176
Cash From Operating Activities 0.357 0.163 0.011 0.009 0.008
Non-Cash Items 19.343 17.413 3.749 0 0.123
Changes in Working Capital 3.022 2.83 -1.505 1.226 -0.11
Cash From Investing Activities 91.479 -275.438 -0.056 0 0
Capital Expenditures -0.363 -1.575 -0.056 0 0
Cash From Financing Activities 0.476 1.391 358.403 0 5.254
Financing Cash Flow Items 0 0
Issuance (Retirement) of Stock, Net 0.476 1.391 355.315 0 4.931
Issuance (Retirement) of Debt, Net 0 3.088 0 0.323
Net Change in Cash 9.89 -324.737 338.481 -3.081 3.078
Other Investing Cash Flow Items, Total 91.842 -273.863
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -28.286 -104.787 -78.608 -55.888 -23.03
Cash From Operating Activities -20.391 -82.065 -62.354 -44.362 -17.903
Cash From Operating Activities 0.1 0.357 0.26 0.169 0.084
Non-Cash Items 4.088 19.343 14.727 10.315 5.294
Changes in Working Capital 3.707 3.022 1.267 1.042 -0.251
Cash From Investing Activities 37.387 91.479 75.143 54.979 25.567
Capital Expenditures 0 -0.363 -0.19 -0.051 -0.03
Other Investing Cash Flow Items, Total 37.387 91.842 75.333 55.03 25.597
Net Change in Cash 17.216 9.89 12.992 10.714 7.697
Cash From Financing Activities 0.22 0.476 0.203 0.097 0.033
Issuance (Retirement) of Stock, Net 0.22 0.476 0.203 0.097 0.033
Financing Cash Flow Items
Issuance (Retirement) of Debt, Net
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BVF Partners L.P. Hedge Fund 16.926 9235449 1623946 2023-09-14 LOW
Paradigm BioCapital Advisors LP Investment Advisor 14.3018 7803600 4072554 2023-09-12 MED
Logos Global Management LLC Investment Advisor 6.8615 3743875 -14943 2023-06-30 HIGH
Cormorant Asset Management, LP Hedge Fund 5.6484 3082000 0 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.4435 1878878 1210899 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.0671 1673522 165755 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.937 1602556 1389244 2023-06-30 LOW
Vivo Capital, LLC Venture Capital 2.4545 1339271 -350244 2023-06-30 LOW
Kynam Capital Management LP Hedge Fund 2.3905 1304332 -707521 2023-06-30 MED
Harmon (Cyrus) Individual Investor 2.0082 1095742 -35000 2023-09-29 LOW
Sectoral Asset Management Inc. Investment Advisor/Hedge Fund 1.1882 648353 -347556 2023-06-30 MED
Citadel Advisors LLC Hedge Fund 1.1665 636475 -594041 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1131 607340 257394 2023-06-30 LOW
Woodline Partners LP Hedge Fund 1.0777 588052 588052 2023-06-30 HIGH
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.0617 579309 3409 2023-06-30 MED
Myles (David C Ph.D.) Individual Investor 1.0297 561821 -20000 2023-09-19
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.9085 495700 374519 2023-06-30 LOW
Rappaport (Andrew) Individual Investor 0.8816 481014 0 2023-04-25
BioImpact Capital LLC Investment Advisor/Hedge Fund 0.8476 462500 462500 2023-06-30 MED
Kovacs Shane William Charles Individual Investor 0.7261 396197 15000 2023-04-25

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Olema Pharmaceuticals, Inc. Company profile

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).

Industry: Biotechnology & Medical Research (NEC)

780 Brannan Street
SAN FRANCISCO
CALIFORNIA 94103
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

72.26 Price
-1.450% 1D Chg, %
Long position overnight fee -0.0225%
Short position overnight fee 0.0006%
Overnight fee time 22:00 (UTC)
Spread 0.040

Gold

2,019.84 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.530% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

15,876.80 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading